dc.contributor.author
LeVine, Dana N.
dc.contributor.author
Goggs, Robert
dc.contributor.author
Kohn, Barbara
dc.contributor.author
Mackin, Andrew J.
dc.contributor.author
Kidd, Linda
dc.contributor.author
Garden, Oliver A.
dc.contributor.author
Brooks, Marjory B.
dc.contributor.author
Eldermire, Erin R. B.
dc.contributor.author
Abrams-Ogg, Anthony
dc.contributor.author
Appleman, Elizabeth H.
dc.date.accessioned
2024-07-29T12:03:51Z
dc.date.available
2024-07-29T12:03:51Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/43974
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-43683
dc.description.abstract
Management of immune thrombocytopenia (ITP) in dogs and cats is evolving, but there are no evidence-based guidelines to assist clinicians with treatment decisions. Likewise, the overall goals for treatment of ITP have not been established. Immunosuppressive doses of glucocorticoids are the first line treatment, but optimal treatment regimens beyond glucocorticoids remain uncertain. Additional options include secondary immunosuppressive drugs such as azathioprine, modified cyclosporine, and mycophenolate mofetil, usually selected based on clinician preference. Vincristine, human IV immunoglobulin (hIVIg), and transfusion of platelet or red blood cell–containing products are often used in more severe cases. Splenectomy and thrombopoietin receptor agonists are usually reserved for refractory cases, but when and in which patient these modalities should be employed is under debate. To develop evidence-based guidelines for individualized treatment of ITP patients, we asked 20 Population Intervention Comparison Outcome (PICO) format questions. These were addressed by 17 evidence evaluators using a literature pool of 288 articles identified by a structured search strategy. Evidence evaluators, using panel-designed templates and data extraction tools, summarized evidence and created guideline recommendations. These were integrated by treatment domain chairs and then refined by iterative Delphi survey review to reach consensus on the final guidelines. In addition, 19 non-PICO questions covering scenarios in which evidence was lacking or of low quality were answered by expert opinion using iterative Delphi surveys with panelist integration and refinement. Commentary was solicited from multiple relevant professional organizations before finalizing the consensus. The rigorous consensus process identified few comparative treatment studies, highlighting many areas of ITP treatment requiring additional studies. This statement is a companion manuscript to the ACVIM Consensus Statement on the Diagnosis of Immune Thrombocytopenia in Dogs and Cats.
en
dc.format.extent
26 Seiten
dc.rights.uri
https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject
glucocorticoids
en
dc.subject
immunoglobulin
en
dc.subject
immunosuppressive
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::630 Landwirtschaft::630 Landwirtschaft und verwandte Bereiche
dc.title
ACVIM consensus statement on the treatment of immune thrombocytopenia in dogs and cats
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.doi
10.1111/jvim.17079
dcterms.bibliographicCitation.journaltitle
Journal of Veterinary Internal Medicine
dcterms.bibliographicCitation.number
4
dcterms.bibliographicCitation.pagestart
1982
dcterms.bibliographicCitation.pageend
2007
dcterms.bibliographicCitation.volume
38
dcterms.bibliographicCitation.url
https://doi.org/10.1111/jvim.17079
refubium.affiliation
Veterinärmedizin
refubium.affiliation.other
Klein- und Heimtierklinik
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.isPartOf.eissn
1939-1676
refubium.resourceType.provider
WoS-Alert